Stay updated on Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.

Latest updates to the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference13%
- Check24 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.3%
- Check38 days agoChange DetectedVersion tag updated from v3.0.1 to v3.0.2; no substantive content changes.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.3%
- Check52 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, while removing specific state, country, and city details. This indicates a shift in how the location is presented, possibly streamlining the information provided.SummaryDifference4%
- Check67 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
Stay in the know with updates to Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.